Claims for Patent: 10,449,145

Summary for Patent: 10,449,145

Title:	Two-layer ocular implant
Abstract:	The present disclosure generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon\'s space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.
Inventor(s):	Csaky; Karl (Dallas, TX)
Assignee:	RETINA FOUNDATION OF THE SOUTHWEST (Dallas, TX)
Application Number:	16/107,059
Patent Claims:	1. An ocular implant comprising a therapeutic agent for treatment or prevention of a disorder of the eye, the implant comprising: a first hardened layer comprising a polymer, the first hardened layer comprising curvature at both surfaces; and a second hardened layer comprising a silicone adhesive and the therapeutic agent, the second hardened layer comprising curvature at both surfaces; wherein the first hardened layer extends circumferentially beyond the second hardened layer such that the surface of the circumferential extension of the first hardened layer is capable of making contact with the sclera of the eye; and wherein at least one surface of the second hardened layer is capable of making contact with the sclera of the eye. 2. The implant of claim 1 wherein the implant is circular or oval shaped. 3. The implant of claim 1 wherein the first hardened layer is resistant to diffusion of the therapeutic agent from the second hardened layer. 4. The implant of claim 1 wherein the first hardened layer is substantially impermeable to diffusion of the therapeutic agent from the second hardened layer. 5. The implant of claim 1 wherein the polymer is polyvinyl acetate, cross-linked polyvinyl alcohol, cross-linked polyvinyl butyrate, ethylene ethylacrylate co-polymer, polyethyl hexylacrylate, polyvinyl chloride, polyvinyl acetals, plasiticized ethylene vinylacetate copolymer, polyvinyl alcohol, polyvinyl acetate, ethylene vinylchloride copolymer, polyvinyl esters, polyvinylbutyrate, polyvinylformal, polyamides, polymethylmethacrylate, polybutylmethacrylate, plasticized polyvinyl chloride, plasticized nylon, plasticized soft nylon, plasticized polyethylene terephthalate, natural rubber, polyisoprene, polyisobutylene, polybutadiene, polyethylene, polytetrafluoroethylene, polyvinylidene chloride, polyacrylonitrile, cross-linked polyvinylpyrrolidone, polytrifluorochloroethylene, chlorinated polyethylene, poly(1,4'-isopropylidene diphenylene carbonate), vinylidene chloride, acrylonitrile copolymer, vinyl chloride-diethyl fumarate copolymer, silicone rubbers, medical grade polydimethylsiloxanes, ethylene-propylene rubber, silicone-carbonate copolymers, vinylidene chloride-vinyl chloride copolymer, vinyl chloride-acrylonitrile copolymer or vinylidene chloride-acrylonitride copolymer. 6. The implant of claim 1 wherein the first hardened layer and the second hardened layer are each about 1 mm thick. 7. The implant of claim 1 wherein the first hardened layer or the second hardened layer further comprise an agent that blocks lymphatic absorption of the therapeutic agent. 8. The implant of claim 1 wherein the second hardened layer further comprises an agent that enhances permeability of the therapeutic agent into the eye. 9. The implant of claim 1 wherein the radius of curvature of a surface of the second hardened layer that is not facing the first hardened layer ranges from between about 5 mm to about 6 mm. 10. The implant of claim 1 which is circular with a diameter ranging between about 1 mm and 8 mm. 11. The implant of claim 1 which is circular with a diameter ranging between about 1 mm and 3 mm. 12. The implant of claim 1 wherein the therapeutic agent is a nuclear factor (erythroid-derived 2)-like 2 enhancer (Nrf2 regulator). 13. The implant of claim 12 wherein the Nrf2 regulator is sulforaphane. 14. The implant of claim 1 wherein the therapeutic agent is selected from the group consisting of fumagillin analogs, minocycline, fluoroquinolone, cephalosporin antibiotics, herbimycin A, tetracycline, chlortetracycline, bacitracin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, gentamicin, erythromycin, antibacterial agents, sulfonamides, sulfacetamide, sulfamethizole, sulfoxazole, nitrofurazone, sodium propionate, antiviral agents, idoxuridine, famvir, trisodium phosphonoformate, trifluorothymidine, acyclovir, ganciclovir, DDI, AZT, protease and integrase inhibitors, anti-glaucoma agents, beta blockers, timolol, betaxolol, atenolol, prostaglandin analogues, hypotensive lipids, carbonic anhydrase inhibitors, antiallergenic agents, antazoline, methapyriline, chlorpheniramine, pyrilamine, prophenpyridamine, anti-inflammatory agents, hydrocortisone, leflunomide, dexamethasone phosphate, fluocinolone acetonide, medrysone, methylprednisolone, prednisolone phosphate, prednisolone acetate, fluoromethalone, betamethasone, triamcinolone acetonide, adrenalcortical steroids and their synthetic analogues, 6-mannose phosphate, antifungal agents, fluconazole, amphotericin B, liposomal amphotericin B, voriconazole, imidazole-based antifungals, tiazole antifungals, echinocandin-like lipopeptide antibiotics, lipid formulations of antifungals, polycations, polyanions, suramine, protamine, decongestants, phenylephrine, naphazoline, tetrahydrazoline, anti-angiogenesis compounds including those that can be potential anti-choroidal neovascularization agents, 2-methoxyestradiol and its analogues, 2-propynl-estradiol,2-propenyl-estradiol, 2-ethoxy-6-oxime-estradiol, 2-hydroxyestrone, 4-methoxyestradiol, VEGF antagonists, VEGF antibodies and VEGF antisense compounds, angiostatic steroids, anecortave acetate and its analogues, 17-ethynylestradiol, norethynodrel, medroxyprogesterone, mestranol, androgens with angiostatic activity, ethisterone, thymidine kinase inhibitors, adrenocortical steroids and their synthetic analogues, fluocinolone acetonide, triamcinolone acetonide, immunological response modifying agents, cyclosporineA, Prograf (tacrolimus), macrolide immunosuppressants, mycophenolate mofetil, rapamycin, muramyl dipeptide, vaccines, anti-cancer agents, 5-fluorouracil, platinum coordination complexes, cisplatin, carboplatin, adriamycin, antimetabolites, methotrexate, anthracycline antibiotics, antimitotic drugs, paclitaxel, docetaxel, epipdophylltoxins, etoposide, nitrosoureas, carmustine, alkylating agents, cyclophosphamide, arsenic trioxide, anastrozole, tamoxifen citrate, triptorelin pamoate, gemtuzumab ozogamicin, irinotecan hydrochloride, leuprolide acetate, bexarotene, exemestrane, epirubicin hydrochloride, ondansetron, temozolomide, topoteanhydrochloride, tamoxifen citrate, irinotecan hydrochloride, trastuzumab, valrubicin, gemcitabine HCl, goserelin acetate, capecitabine, aldesleukin, rituximab, oprelvekin, interferon alfa-2a, letrozole, toremifene citrate, mitoxantrone hydrochloride, irinotecan HeL, topotecan HCl, etoposide phosphate, amifostine, antisense agents, antimycotic agents, miotic and anticholinesterase agents, pilocarpine, eserine salicylate, carbachol, diisopropyl fluorophosphate, phospholine iodine, demecarium bromide, mydriatic agents, differentiation modulator agents, sympathomimetic agents epinephrine, anesthetic agents, lidocaine, benzodiazepam, vasoconstrictive agents, vasodilatory agents, polypeptides, protein agents, angiostatin, endostatin, matrix metalloproteinase inhibitors, platelet factor 4, interferon-gamma, insulin, growth hormones, insulin related growth factor, heat shock proteins, humanized antiIL2 receptor mAb (Daclizumab), etanercept, mono and polyclonal antibodies, cytokines, antibodies to cytokines, neuroprotective agents, cell transport/mobility impending agents, colchicine, vincristine, cytochalasin B, carbonic anhydrase inhibitor agents, integrin antagonists, lipophilic agents, and lubricating agents. 15. The implant of claim 1 wherein the first hardened layer and/or the second hardened layer further comprise a nutraceutical oil. 16. The implant of claim 1 wherein the second hardened layer further comprises an ophthalmic permeation agent that increases ocular permeability of the therapeutic agent into the eye. 17. The implant of claim 1 wherein the second hardened layer comprises an excipient that improves the release of the therapeutic agent. 18. The implant of claim 17 wherein the excipient is selected from one or more of isopropyl myristate, levomenthol, propylene and tetraglycol. 19. The implant of claim 1, wherein the first hardened layer and the second hardened layer are bound together by the silicone adhesive of the second hardened layer or by using a pressure sensitive silicone adhesive other than silicone adhesive of the second hardened layer.

Details for Patent 10,449,145

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Hoffmann-la Roche Inc.	ROFERON-A	interferon alfa-2a	For Injection	103145	06/04/1986		2033-05-02
Clinigen, Inc.	PROLEUKIN	aldesleukin	For Injection	103293	05/05/1992		2033-05-02
Wyeth Pharmaceuticals Inc.	NEUMEGA	oprelvekin	For Injection	103694	11/25/1997		2033-05-02
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2033-05-02
Hoffmann-la Roche Inc.	ZENAPAX	daclizumab	Injection	103749	12/10/1997		2033-05-02
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2033-05-02
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2033-05-02